ClinicalTrials.gg
CompletedNCT03594747Updated Oct 26, 2024Results posted

A Study of Tislelizumab in Combination With Chemotherapy Versus Chemotherapy in Advanced Lung Cancer

A Phase 3 interventional study of Tislelizumab and Paclitaxel in Non-Small Cell Lung Cancer, sponsored by BeiGene. Completed at 43 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-10-26.

Sponsored by BeiGene · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
360
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 41 studies testing tislelizumab in Carcinoma, Non-Small-Cell Lung — 20 open to participants now, 22 under way, 2 of them phase 3. tislelizumab · Carcinoma, Non-Small-Cell Lung.

Enrollment
6th of 41
360 · median 39
Started
2018
with 1 other
Phase 3
9 of 41
none open now
Registered
2nd of 41
by date
Lead sponsor
10 of 41
BeiGene

Among the 41 studies testing tislelizumab in Carcinoma, Non-Small-Cell Lung, this one is the 6th largest by enrollment, is one of 2 that started in 2018, is one of 9 in phase 3, and was the 2nd registered.

Carcinoma, Non-Small-Cell Lung

7,635 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,840 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

20 of the 41 studies testing tislelizumab in Carcinoma, Non-Small-Cell Lung are open now, in 1 country. Recruiting first, the newest first:

15 more — sign in →

By country, each count listing its studies:

All 20 open studies →

About tislelizumab

tislelizumab: first FDA approval 2024 (TEVIMBRA), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 989 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies testing tislelizumab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

An open-label, randomized, multicenter Phase 3 study designed to compare the efficacy and safety of tislelizumab combined with chemotherapy versus chemotherapy only as first-line treatment in advanced squamous non-small cell lung cancer (NSCLC).

03

Conditions studied

  • Non-Small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Age 18-75 years old, male or female, and signed form (ICF)
  2. Advanced NSCLC diagnosed by pathological or clinical physicians
  3. (ECOG) performance status (PS) ≤ 1
  4. Participants must have ≥ 1 as defined per (RECIST) v1.1
  5. Must be treatment-naive for locally advanced or squamous NSCLC
  6. ≥ 12 weeks
  7. Participants must have adequate organ function
  8. Male/Female is willing to use a highly effective method of

Key Exclusion Criteria:

  1. Diagnosed with NSCLC but with epidermal growth factor receptors (EGFR)-sensitizing mutation or anaplastic lymphoma kinase (ALK) gene translocation
  2. Received any approved systemic anticancer therapy
  3. Received prior treatment with EGFR inhibitors or ALK inhibitors
  4. Received prior therapies targeting programmed death 1 () or programmed death ligand 1 (PD-L1)
  5. With history of interstitial lung disease
  6. pericardial effusion
  7. Severe infections, active or uncontrolled, untreated
  8. Any major surgical procedure before randomization
  9. infection
  10. Untreated virus (HBV)/ virus (HCV)
  11. Active diseases or history of autoimmune diseases
  12. History of allergic reactions to chemotherapy

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
360 participants (actual)

Study arms

  • Experimental
    Tislelizumab + Paclitaxel + Carboplatin

    Tislelizumab 200 milligrams (mg) plus paclitaxel 175 mg/m\^2 and carboplatin area under the plasma or serum concentration-time curve (AUC) 5 on Day 1 administered intravenously once every 3 weeks until unacceptable toxicity, withdrawal of consent, loss of clinical benefit, or disease progression; paclitaxel and carboplatin were administered for 4 to 6 cycles (each cycle is 21 days)

    Drug: Tislelizumab · Drug: Paclitaxel · Drug: Carboplatin

  • Experimental
    Tislelizumab + Nab-paclitaxel + Carboplatin

    Tislelizumab 200 mg on Day 1 plus Nab-paclitaxel 100 mg/m\^2 on Days 1, 8, and 15 and carboplatin AUC 5 on Day 1 administered intravenously once every 3 weeks until unacceptable toxicity, withdrawal of consent, loss of clinical benefit, or disease progression; Nab-paclitaxel and carboplatin were administered for 4 to 6 cycles (each cycle is 21 days)

    Drug: Tislelizumab · Drug: Nab-paclitaxel · Drug: Carboplatin

  • Active comparator
    Paclitaxel + Carboplatin

    Paclitaxel 175 mg/m\^2 and carboplatin AUC 5 on Day 1 administered intravenously once every 3 weeks for 4 to 6 cycles (each cycle is 21 days)

    Drug: Paclitaxel · Drug: Carboplatin

Interventions

  • Administered intravenously as described

    Also known as: BGB-A317, Tevimbra

  • Administered intravenously as described

  • Administered intravenously as described

  • Administered intravenously as described

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS) by Independent Review Committee (IRC) Assessment as of Data Cut-off Date of 06DEC2019

    PFS is defined as the time from randomization until first documentation of disease progression as assessed by the IRC per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or death from any cause, whichever occurs first

    Time frame: Through primary analysis data cut-off date of 06DEC2019 (up to approximately 1 year and 4 months)

  2. PFS by IRC Assessment as of Data Cut-off Date of 30SEP2020

    PFS is defined as the time from randomization until first documentation of disease progression as assessed by the IRC per RECIST v1.1 or death from any cause, whichever occurs first

    Time frame: Through primary analysis data cut-off date of 30SEP2020 (up to approximately 2 years and 2 months)

Secondary outcomes

  1. Overall Survival (OS)

    OS is defined as the time from randomization until the date of death due to any cause

    Time frame: Through study completion data cut-off date of 28APR2023 (up to approximately 4 years and 9 months)

  2. Objective Response Rate (ORR) by IRC Assessment

    ORR is defined as the percentage of participants with complete response (CR) and partial response (PR), as assessed by the IRC using RECIST v1.1.

    Time frame: Through study completion data cut-off date of 28APR2023 (up to approximately 4 years and 9 months)

  3. ORR by Investigator Assessment

    ORR is defined as the percentage of participants with complete response (CR) and partial response (PR), as assessed by the investigator using RECIST v1.1.

    Time frame: Through study completion data cut-off date of 28APR2023 (up to approximately 4 years and 9 months)

  4. Duration of Response (DOR) by IRC Assessment

    DOR is defined as the time from the first occurrence of a documented objective response to the time of documented disease progression assessed by the IRC using RECIST v1.1, or death from any cause, whichever comes first, in all randomized participants with documented objective responses. Data are based on number of responders.

    Time frame: Through study completion data cut-off date of 28APR2023 (up to approximately 4 years and 9 months)

  5. DOR by Investigator Assessment

    DOR is defined as the time from the first occurrence of a documented objective response to the time of documented disease progression assessed by the investigator using RECIST v1.1, or death from any cause, whichever comes first, in all randomized participants with documented objective responses. Data are based on number of responders.

    Time frame: Through study completion data cut-off date of 28APR2023 (up to approximately 4 years and 9 months)

  6. PFS by Investigator Assessment

    PFS is defined as the time from randomization until first documentation of disease progression as assessed by the investigator per RECIST v1.1 or death from any cause, whichever occurs first

    Time frame: Through study completion data cut-off date of 28APR2023 (up to approximately 4 years and 9 months)

  7. PFS by IRC Based on Programmed Death Ligand 1 (PD-L1) Expression

    PFS is defined as the time from randomization until first documentation of disease progression as assessed by the IRC per RECIST v1.1 or death from any cause, whichever occurs first, based on PD-L1 expression in tumor cells

    Time frame: Through study completion data cut-off date of 28APR2023 (up to approximately 4 years and 9 months)

  8. European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Lung Cancer (EORTC QLQ-LC13)

    Least squares mean change from baseline in EORTC QLQ-CL13 scores for chest pain, coughing, and dyspnea between tislelizumab arms and paclitaxel + carboplatin arm. The EORTC QLQ-LC13 is a questionnaire that measures lung cancer-specific disease and treatment symptoms. It includes questions about specific symptoms in which participants respond based on a 4-point scale, where 1 is "not at all" and 4 is "very much". Raw scores are transformed into a 0 to 100 scale via linear transformation. A lower score indicates an improvement in symptoms.

    Time frame: Baseline to Cycle 5; each cycle is 21 days

  9. European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Global Health Status

    Least squares mean change from baseline in EORTC QLQ-C30 Global Health Status/Quality of Life score between tislelizumab arms and paclitaxel + carboplatin arm. The EORTC QLQ-C30 v3.0 is a questionnaire that assesses quality of life of cancer patients. It includes global health status and quality of life questions related to overall health in which participants respond based on a 7-point scale, where 1 is very poor and 7 is excellent. Raw scores are transformed into a 0 to 100 scale via linear transformation. A higher score indicates better health outcomes.

    Time frame: Baseline to Cycle 5; each cycle is 21 days

  10. Number of Participants With Adverse Events

    Number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs), which includes laboratory tests, physical exams, electrocardiogram results and vital signs, according to National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0

    Time frame: From first dose to 30 days after the last dose (up to approximately 4 years and 9 months)

07

Results

Posted Oct 17, 2023

Participant flow

This study was conducted at multiple study centers in China. Data are presented as of the study completion data cut-off date of 28APR2023.

Participant flow — Overall Study
MilestoneTislelizumab + Paclitaxel + CarboplatinTislelizumab + Nab-paclitaxel + CarboplatinPaclitaxel + Carboplatin
Started120119121
Randomized but not treated014
Completed000
Not completed120119121
Withdrew: Death788687
Withdrew: Withdrawal by subject5211
Withdrew: Lost to follow-up411
Withdrew: Physician decision010
Withdrew: Sponsor decision231716
Withdrew: Did not meet inclusion criteria001
Withdrew: Transfer to long term extension study10125

Outcome measures

PrimaryProgression Free Survival (PFS) by Independent Review Committee (IRC) Assessment as of Data Cut-off Date of 06DEC2019

PFS is defined as the time from randomization until first documentation of disease progression as assessed by the IRC per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or death from any cause, whichever occurs first

Time frame:
Through primary analysis data cut-off date of 06DEC2019 (up to approximately 1 year and 4 months)
Reported as:
Median · Months
Progression Free Survival (PFS) by Independent Review Committee (IRC) Assessment as of Data Cut-off Date of 06DEC2019
MonthsTislelizumab + Paclitaxel + CarboplatinTislelizumab + Nab-paclitaxel + CarboplatinPaclitaxel + Carboplatin
Progression Free Survival (PFS) by Independent Review Committee (IRC) Assessment as of Data Cut-off Date of 06DEC20197.6 (5.95 to 9.79)7.6 (5.75 to 11.01)5.5 (4.21 to 5.65)
Statistical analysis
  • Tislelizumab + Paclitaxel + Carboplatin vs Paclitaxel + Carboplatin · One-sided stratified log-rank test · p = 0.0001 · Hazard ratio (hr): 0.52 · 95% CI 0.37 to 0.74
  • Tislelizumab + Nab-paclitaxel + Carboplatin vs Paclitaxel + Carboplatin · One-sided stratified log-rank test · p = <0.0001 · Hazard ratio (hr): 0.47 · 95% CI 0.33 to 0.67
PrimaryPFS by IRC Assessment as of Data Cut-off Date of 30SEP2020

PFS is defined as the time from randomization until first documentation of disease progression as assessed by the IRC per RECIST v1.1 or death from any cause, whichever occurs first

Time frame:
Through primary analysis data cut-off date of 30SEP2020 (up to approximately 2 years and 2 months)
Reported as:
Median · Months
PFS by IRC Assessment as of Data Cut-off Date of 30SEP2020
MonthsTislelizumab + Paclitaxel + CarboplatinTislelizumab + Nab-paclitaxel + CarboplatinPaclitaxel + Carboplatin
PFS by IRC Assessment as of Data Cut-off Date of 30SEP20207.7 (6.74 to 10.41)9.6 (7.39 to 10.78)5.5 (4.21 to 5.59)
Statistical analysis
  • Tislelizumab + Paclitaxel + Carboplatin vs Paclitaxel + Carboplatin · Hazard ratio (hr): 0.45 · 95% CI 0.32 to 0.61
  • Tislelizumab + Nab-paclitaxel + Carboplatin vs Paclitaxel + Carboplatin · Hazard ratio (hr): 0.42 · 95% CI 0.30 to 0.59
SecondaryOverall Survival (OS)

OS is defined as the time from randomization until the date of death due to any cause

Time frame:
Through study completion data cut-off date of 28APR2023 (up to approximately 4 years and 9 months)
Reported as:
Median · Months
Overall Survival (OS)
MonthsTislelizumab + Paclitaxel + CarboplatinTislelizumab + Nab-paclitaxel + CarboplatinPaclitaxel + Carboplatin
Overall Survival (OS)26.1 (18.99 to 33.81)23.3 (18.76 to 26.38)19.4 (15.97 to 23.43)
SecondaryObjective Response Rate (ORR) by IRC Assessment

ORR is defined as the percentage of participants with complete response (CR) and partial response (PR), as assessed by the IRC using RECIST v1.1.

Time frame:
Through study completion data cut-off date of 28APR2023 (up to approximately 4 years and 9 months)
Reported as:
Number · Percentage of participants
Objective Response Rate (ORR) by IRC Assessment
Percentage of participantsTislelizumab + Paclitaxel + CarboplatinTislelizumab + Nab-paclitaxel + CarboplatinPaclitaxel + Carboplatin
Objective Response Rate (ORR) by IRC Assessment74.2 (65.4 to 81.7)73.9 (65.1 to 81.6)47.9 (38.8 to 57.2)
SecondaryORR by Investigator Assessment

ORR is defined as the percentage of participants with complete response (CR) and partial response (PR), as assessed by the investigator using RECIST v1.1.

Time frame:
Through study completion data cut-off date of 28APR2023 (up to approximately 4 years and 9 months)
Reported as:
Number · Percentage of participants
ORR by Investigator Assessment
Percentage of participantsTislelizumab + Paclitaxel + CarboplatinTislelizumab + Nab-paclitaxel + CarboplatinPaclitaxel + Carboplatin
ORR by Investigator Assessment70.0 (61.0 to 78.0)78.2 (69.6 to 85.2)49.6 (40.4 to 58.8)
SecondaryDuration of Response (DOR) by IRC Assessment

DOR is defined as the time from the first occurrence of a documented objective response to the time of documented disease progression assessed by the IRC using RECIST v1.1, or death from any cause, whichever comes first, in all randomized participants with documented objective responses. Data are based on number of responders.

Time frame:
Through study completion data cut-off date of 28APR2023 (up to approximately 4 years and 9 months)
Reported as:
Median · Months
Duration of Response (DOR) by IRC Assessment
MonthsTislelizumab + Paclitaxel + CarboplatinTislelizumab + Nab-paclitaxel + CarboplatinPaclitaxel + Carboplatin
Duration of Response (DOR) by IRC Assessment8.4 (5.03 to 18.69)8.6 (7.13 to 12.48)4.3 (2.86 to 5.42)
SecondaryDOR by Investigator Assessment

DOR is defined as the time from the first occurrence of a documented objective response to the time of documented disease progression assessed by the investigator using RECIST v1.1, or death from any cause, whichever comes first, in all randomized participants with documented objective responses. Data are based on number of responders.

Time frame:
Through study completion data cut-off date of 28APR2023 (up to approximately 4 years and 9 months)
Reported as:
Median · Months
DOR by Investigator Assessment
MonthsTislelizumab + Paclitaxel + CarboplatinTislelizumab + Nab-paclitaxel + CarboplatinPaclitaxel + Carboplatin
DOR by Investigator Assessment10.6 (7.03 to 16.23)8.8 (8.05 to 11.93)4.8 (2.86 to 6.11)
SecondaryPFS by Investigator Assessment

PFS is defined as the time from randomization until first documentation of disease progression as assessed by the investigator per RECIST v1.1 or death from any cause, whichever occurs first

Time frame:
Through study completion data cut-off date of 28APR2023 (up to approximately 4 years and 9 months)
Reported as:
Median · Months
PFS by Investigator Assessment
MonthsTislelizumab + Paclitaxel + CarboplatinTislelizumab + Nab-paclitaxel + CarboplatinPaclitaxel + Carboplatin
PFS by Investigator Assessment9.6 (7.62 to 11.76)9.8 (8.57 to 11.86)5.5 (4.17 to 5.65)
SecondaryPFS by IRC Based on Programmed Death Ligand 1 (PD-L1) Expression

PFS is defined as the time from randomization until first documentation of disease progression as assessed by the IRC per RECIST v1.1 or death from any cause, whichever occurs first, based on PD-L1 expression in tumor cells

Time frame:
Through study completion data cut-off date of 28APR2023 (up to approximately 4 years and 9 months)
Reported as:
Median · Months
PFS by IRC Based on Programmed Death Ligand 1 (PD-L1) Expression
MonthsTislelizumab + Paclitaxel + CarboplatinTislelizumab + Nab-paclitaxel + CarboplatinPaclitaxel + Carboplatin
PD-L Expression (<1%)7.6 (5.5 to 14.5)7.6 (5.4 to 9.9)5.5 (4.2 to 7.0)
PD-L Expression (1% to 49%)9.9 (5.5 to 22.7)9.8 (7.6 to 12.0)5.0 (2.8 to 6.5)
PD-L Expression (≥ 50%)7.7 (5.9 to 9.8)9.7 (5.6 to 30.9)5.5 (4.1 to 5.6)
SecondaryEuropean Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Lung Cancer (EORTC QLQ-LC13)

Least squares mean change from baseline in EORTC QLQ-CL13 scores for chest pain, coughing, and dyspnea between tislelizumab arms and paclitaxel + carboplatin arm. The EORTC QLQ-LC13 is a questionnaire that measures lung cancer-specific disease and treatment symptoms. It includes questions about specific symptoms in which participants respond based on a 4-point scale, where 1 is "not at all" and 4 is "very much". Raw scores are transformed into a 0 to 100 scale via linear transformation. A lower score indicates an improvement in symptoms.

Time frame:
Baseline to Cycle 5; each cycle is 21 days
Reported as:
Least squares mean · Score on a scale
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Lung Cancer (EORTC QLQ-LC13)
Score on a scaleTislelizumab + Paclitaxel + CarboplatinTislelizumab + Nab-paclitaxel + Carboplatin
Chest pain0.4 (-5.0 to 5.9)-0.4 (-5.9 to 5.1)
Coughing-7.0 (-14.3 to 0.2)-0.4 (-7.7 to 6.8)
Dyspnea-2.7 (-6.9 to 1.6)-1.0 (-5.3 to 3.3)
SecondaryEuropean Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Global Health Status

Least squares mean change from baseline in EORTC QLQ-C30 Global Health Status/Quality of Life score between tislelizumab arms and paclitaxel + carboplatin arm. The EORTC QLQ-C30 v3.0 is a questionnaire that assesses quality of life of cancer patients. It includes global health status and quality of life questions related to overall health in which participants respond based on a 7-point scale, where 1 is very poor and 7 is excellent. Raw scores are transformed into a 0 to 100 scale via linear transformation. A higher score indicates better health outcomes.

Time frame:
Baseline to Cycle 5; each cycle is 21 days
Reported as:
Least squares mean · Score on a scale
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Global Health Status
Score on a scaleTislelizumab + Paclitaxel + CarboplatinTislelizumab + Nab-paclitaxel + Carboplatin
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Global Health Status2.4 (-3.4 to 8.2)3.3 (-2.5 to 9.2)
SecondaryNumber of Participants With Adverse Events

Number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs), which includes laboratory tests, physical exams, electrocardiogram results and vital signs, according to National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0

Time frame:
From first dose to 30 days after the last dose (up to approximately 4 years and 9 months)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events
ParticipantsTislelizumab + Paclitaxel + CarboplatinTislelizumab + Nab-paclitaxel + CarboplatinPaclitaxel + Carboplatin
At least 1 TEAE120117117
At least 1 SAE565529

Adverse events

Collected over From the first dose up to 30 days after the last dose of study drug, up to approximately 4 years and 9 months. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tislelizumab + Paclitaxel + Carboplatin78/120 (65%)56/120 (46.7%)119/120 (99.2%)
Tislelizumab + Nab-Paclitaxel + Carboplatin86/119 (72.3%)55/118 (46.6%)117/118 (99.2%)
Paclitaxel + Carboplatin87/121 (71.9%)29/117 (24.8%)116/117 (99.1%)
Most frequent serious events
Showing 10 of 95
Most frequent serious events
EventTislelizumab + Paclitaxel + CarboplatinTislelizumab + Nab-Paclitaxel + CarboplatinPaclitaxel + Carboplatin
PneumoniaInfections and infestations12/1207/1185/117
PneumonitisRespiratory, thoracic and mediastinal disorders6/1207/1180/117
Febrile neutropeniaBlood and lymphatic system disorders2/1204/1181/117
Neutrophil count decreasedInvestigations4/1204/1182/117
HaemoptysisRespiratory, thoracic and mediastinal disorders4/1204/1181/117
ThrombocytopeniaBlood and lymphatic system disorders2/1201/1183/117
AnaemiaBlood and lymphatic system disorders1/1201/1182/117
DeathGeneral disorders1/1202/1182/117
PyrexiaGeneral disorders2/1201/1182/117
Septic shockInfections and infestations0/1201/1182/117
Most frequent other events
Showing 10 of 126
Most frequent other events
EventTislelizumab + Paclitaxel + CarboplatinTislelizumab + Nab-Paclitaxel + CarboplatinPaclitaxel + Carboplatin
AnaemiaBlood and lymphatic system disorders107/120111/11894/117
AlopeciaSkin and subcutaneous tissue disorders78/12082/11872/117
Neutrophil count decreasedInvestigations78/12073/11868/117
White blood cell count decreasedInvestigations68/12068/11861/117
LeukopeniaBlood and lymphatic system disorders58/12066/11857/117
NeutropeniaBlood and lymphatic system disorders53/12050/11856/117
Alanine aminotransferase increasedInvestigations57/12046/11827/117
Decreased appetiteMetabolism and nutrition disorders55/12055/11837/117
NauseaGastrointestinal disorders37/12054/11835/117
Platelet count decreasedInvestigations45/12054/11829/117

Baseline characteristics

Intent-to-treat (ITT) analysis set included all participants who were randomized. Data are presented as of the study completion data cut-off date of 28APR2023.

Age, Continuous
Age, Continuous(Years)Tislelizumab + Paclitaxel + CarboplatinTislelizumab + Nab-paclitaxel + CarboplatinPaclitaxel + CarboplatinTotal
Median60.0 (41 to 75)64.0 (38 to 74)63.0 (34 to 75)62.5 (34 to 75)
Sex: Female, Male
Sex: Female, Male(Participants)Tislelizumab + Paclitaxel + CarboplatinTislelizumab + Nab-paclitaxel + CarboplatinPaclitaxel + CarboplatinTotal
Female1371030
Male107112111330
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Tislelizumab + Paclitaxel + CarboplatinTislelizumab + Nab-paclitaxel + CarboplatinPaclitaxel + CarboplatinTotal
Asian120119121360
Not Hispanic or Latino120119121360
08

Study locations

43 sites
  • Anhui Provincial Hospital
    Hefei, Anhui 230000, China
  • The First Affiliated Hospital of Anhui Medical University
    Hefei, Anhui 230000, China
  • Cancer Hospital Chinese Academy of Medical Sciences
    Beijing, Beijing 100021, China
  • Beijing Cancer Hospital
    Beijing, Beijing 100142, China
  • Peking Union Medical College Hospital
    Beijing, Beijing 100730, China
  • Chinese Pla General Hospital
    Beijing, Beijing 100853, China
  • Beijing Chest Hospital, Capital Medical University
    Beijing, Beijing 101149, China
  • The Second Affiliated Hospital of Chongqing Medical University
    Chongqing, Chongqing 400010, China
  • Southwest Hospital
    Chongqing, Chongqing 400038, China
  • Daping Hospital, Third Military Medical University
    Chongqing, Chongqing 400042, China
  • Chongqing Three Gorges Central Hospital
    Chongqing, Chongqing 404000, China
  • Fujian Cancer Hospital
    Fuzhou, Fujian 350014, China
  • The First Affiliated Hospital of Xiamen University
    Xiamen, Fujian 361003, China
  • Nanfang Hospital of Southern Medical University
    Guangzhou, Guangdong 510515, China
  • Cancer Hospital of Shantou University Medical College
    Shantou, Guangdong 515031, China
  • The Peoples Hospital of Guangxi Zhuang Autonomous Region
    Nanning, Guangxi 530021, China
  • The Affiliated Hospital of Zunyi Medical College
    Zunyi, Guizhou 563000, China
  • Harbin Medical University Cancer Hospital
    Harbin, Heilongjiang 150000, China
  • Henan Cancer Hospital
    Zhengzhou, Henan 450000, China
  • The First Affiliated Hospital of Zhengzhou University
    Zhengzhou, Henan 450052, China
  • Union Hospital of Tongji Medical College, Huazhong University of Science and Technology
    Wuhan, Hubei 430022, China
  • Hubei Cancer Hospital
    Wuhan, Hubei 430079, China
  • The Second Xiangya Hospital of Central South University
    Changsha, Hunan 410011, China
  • Hunan Cancer Hospital
    Changsha, Hunan 410013, China
  • General Hospital of Eastern Theater Command
    Nanjing, Jiangsu 210002, China
  • The First Affiliated Hospital of Soochow University
    Suzhou, Jiangsu 215006, China
  • Xuzhou Central Hospital
    Xuzhou, Jiangsu 221000, China
  • The First Hospital of Jilin University
    Changchun, Jilin 130021, China
  • Liaoning Cancer Hospital and Institute
    Shenyang, Liaoning 110042, China
  • The First Affiliated Hospital of Xian Jiaotong University
    Xian, Shaanxi 710061, China
  • Qilu Hospital of Shandong University
    Jinan, Shandong 250000, China
  • Jinan Central Hospital
    Jinan, Shandong 250013, China
  • Jinan Military General Hospital
    Jinan, Shandong 250031, China
  • Shandong Cancer Hospital
    Jinan, Shandong 250117, China
  • Weifang Peoples Hospital
    Weifang, Shandong 261000, China
  • Shanghai Chest Hospital
    Shanghai, Shanghai 200030, China
  • West China Hospital, Sichuan University
    Chengdu, Sichuan 610041, China
  • Tianjin Medical University General Hospital
    Tianjin, Tianjin 300052, China
  • Tianjin Medical University Cancer Institute and Hospital
    Tianjin, Tianjin 300060, China
  • The First Affiliated Hospital, Zhejiang University School of Medicine
    Hangzhou, Zhejiang 310003, China
  • Hangzhou First Peoples Hospital
    Hangzhou, Zhejiang 310006, China
  • Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
    Hangzhou, Zhejiang 310016, China
  • Zhejiang Cancer Hospital
    Hangzhou, Zhejiang 310022, China
09

References and documents

Publications

  • Wang J, Lu S, Yu X, Hu Y, Sun Y, Wang Z, Zhao J, Yu Y, Hu C, Yang K, Feng G, Ying K, Zhuang W, Zhou J, Wu J, Leaw SJ, Zhang J, Lin X, Liang L, Yang N. Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non-Small-Cell Lung Cancer: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2021 May 1;7(5):709-717. doi: 10.1001/jamaoncol.2021.0366. PubMed 33792623 ↗
  • Wang, J, S. Lu, et al. Randomized Phase III Study of Tislelizumab plus Chemotherapy versus Chemotherapy Alone as First-Line Treatment for Advanced Squamous Non-Small Cell Lung Cancer (Sq-NSCLC): RATIONALE-307 Updated Analysis. IOTECH Abstract, Vol. 16 Supplement 1, Dec. 2022. doi.org/10.1016/j.iotech.2022.100244.

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2018 to primary completion in Sep 2020, 26 months.

Results were first posted in Oct 2023, 3 years after primary completion. A results delay was requested in Sep 2021.

Of 314 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's 26 months is below that.

Counting every sponsor, half of 423 studies reached it within 45 months; a quarter within 30 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 3, 2018
First posted
Jul 20, 2018
StartActual
Jul 30, 2018
Primary completionActual
Sep 30, 2020
CompletionActual
Apr 28, 2023
Results delay requested
Sep 24, 2021
Results first posted
Oct 17, 2023
Last update
Oct 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03594747
Lead sponsor
BeiGene
Responsible party
Sponsor
First posted
Jul 20, 2018
Start date
Jul 30, 2018
Primary completion
Sep 30, 2020
Completion
Apr 28, 2023
Results posted
Oct 17, 2023
Last update
Oct 26, 2024

Study contacts

Study Director
study director · BeiGene

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tislelizumab · Paclitaxel · Albumin-Bound Paclitaxel

Start the discussion